The Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields,” to inhibit cancer cell replication and cause cancer cell death.
The new reimbursement win brings the number of commercial payers covering Optune treatment up to 9, NovoCure said in a press release.
In January, NovoCure said it applied for a supplemental pre-market approval from the FDA for the 2nd generation of its Optune device for treating glioblastoma, a form of brain cancer.
The FDA approved Optune’s 1st iteration in April 2011. NovoCure said it pared the weight of the newer version, which hit the European market last October, from 6 pounds to 2.7 pounds using digital signal generation technology.
Last December, NovoCure touted positive data from a pivotal Phase III trial of the Optune device in combination with standard-of-care temozolomide for treating newly diagnosed glioblastoma, which was halted early for success.